Use-Side Compliance for Private Healthcare Facilities: The Cap. 633 Code of Practice

1. Key takeaways

Licensed private healthcare facilities under the Private Healthcare Facilities Ordinance (Cap. 633), namely private hospitals, day procedure centres and licensed clinics, are bound by a code of practice. The Department of Health has announced that the revised code of practice is scheduled to be gazetted in the fourth quarter of 2026 and to take effect 1 month after gazettal, except for the device-related part. The requirement to use injectable and infusible medical devices that are listed under MDACS takes effect on 1 March 2027.

Section 47 of Cap. 633 provides that the licensee is responsible for the operation of the facility, including compliance with the code of practice. That provision is the legal fulcrum on which the requirement rests: without it, a code of practice would be guidance; with it, the code becomes a condition of holding a licence.

For a manufacturer, the rule is directed at the user rather than at the supplier, and that is precisely why it matters. A licensed facility that must use listed devices will require its suppliers to provide listed devices, and will remove products that cannot be verified. The obligation is not addressed to the manufacturer, but the commercial consequence arrives at the manufacturer.

2. Legal basis

The Private Healthcare Facilities Ordinance, Cap. 633, at section 47, places responsibility for the operation of the facility on the licensee, including compliance with the code of practice, and Schedule 3, columns 2 and 3, sets out the procedures concerned. The letter from the Office for Regulation of Private Healthcare Facilities of the Department of Health, dated 9 September 2026 and titled Update on Regulatory Requirements on the Use of Injectable and Infusible Products in Licensed Private Healthcare Facilities, addresses the three categories at item A1, the requirements under Cap. 465 and Cap. 633 at item A3, and the effective date of 1 March 2027 at item A4. The government press release on the revision of the code of practice for licensed private healthcare facilities, published on 29 September 2026, records the fourth-quarter gazettal, the one-month commencement after gazettal and the 1 March 2027 arrangement. The Human Organ Transplant Ordinance, Cap. 465, contains the provisions regulating human organ and human tissue products, and the MDACS scheme page carries the explanation of the public listing lists.

The two-layer structure is what makes the timeline enforceable. The ordinance supplies the duty through section 47; the code of practice supplies the technical content; and the announcement supplies the dates. Each layer is necessary, and a supplier that reads only the announcement will not see why a hospital is prepared to terminate a supply relationship over a listing status.

3. Expert insights

This is a use-side rule transmitted upstream through the supply chain. The rule binds licensed facilities, but a facility that must meet it will in practice require its suppliers to provide listed products. For manufacturers this is a market threshold that carries no penalty of its own yet has real force, because the penalty falls on the customer rather than on the supplier. Suppliers that understand this negotiate differently: the question is not whether the regulator will pursue them, but whether the hospital will keep buying.

Section 47 leaves the facility no room to look away. The licensee is responsible for the operation of the facility, including compliance with the code of practice, and compliance with the code is a condition for the issue and renewal of a licence. A facility therefore has a strong incentive to clear unlisted products from use proactively, rather than to wait for an inspection finding that could affect its licence.

Human tissue products face a double restriction. In addition to Cap. 465, transplanting any cells, tissue or organs is a procedure described in column 2 of Schedule 3 to Cap. 633, and except for the procedures listed in column 3, injection or infusion may not be carried out in a clinic. A product of this kind cannot circumvent the restriction by finding a clinic willing to administer it, because the restriction attaches to the procedure and to the premises rather than to the supplier relationship.

The timeline leaves manufacturers very little room. Gazettal is expected in the fourth quarter of 2026 and commencement is on 1 March 2027. Working backwards from the 12-week assessment plus 2 weeks for acknowledgement, the submission window is effectively the fourth quarter of 2026, a practical estimate rather than a published deadline. A manufacturer that begins preparing a dossier in January 2027 will not have a listed product by the commencement date.

The gazetted text still has to be checked. The announcement establishes the dates and the principle; the final wording of the device-related part will appear only in the gazetted code. Manufacturers should verify the final text against the position described in the letter of 9 September 2026, since a difference in wording at that stage would change the scope of what facilities are required to use.

4. Practical recommendations

• Start the injectable and infusible product inventory now. Assess each model on whether it is a medical device, and place any device immediately into a listing plan with a dated target.
• Schedule submission for the fourth quarter of 2026. Compress LRP appointment, MDIS account opening and dossier preparation into that quarter, so that the 12-week assessment finishes before 1 March 2027.
• Give facility customers a listing status statement. Communicate status proactively, since early notice is what prevents a product from appearing on a facility clearance list.
• Monitor the gazetted text. After gazettal in the fourth quarter, check the final wording of the device section against the letter of 9 September 2026 and record any difference.
• Screen tissue-based products separately. Where a product contains human tissue components, check Cap. 465 and Schedule 3 to Cap. 633 before assuming that a clinic setting is available.

5. Verification checklist

• □ Attribute and classification assessment completed for all injectable and infusible products.
• □ Submission timetable set backwards from 1 March 2027.
• □ LRP appointment and MDIS account opening initiated.
• □ Listing progress statement issued to licensed facility customers.
• □ Gazettal progress of the code of practice tracked and published text retained.
• □ Products containing human tissue components checked against Cap. 465 and Schedule 3 to Cap. 633.
• □ Final gazetted wording compared with the position stated in the letter of 9 September 2026.

Regulatory information verified as at 29 October 2026 against the official sources listed under legal basis; where those sources are updated, the latest published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team coordinates local responsible persons, import and wholesale dealer licensing, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com